Challenges and Solutions to Manufacturing of Low-Viscosity, Ultra-High Concentration IgG1 Drug Products: From Late Downstream Process to Final Fill Finish Processing

References

1. 1.↵
   Global Monoclonal Antibodies (Mabs) Market Data and Industry Growth Analysis. https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report (accessed January 17, 2023).
2. 2.↵
   Information on approval of new antibody. https://www.antibodysociety.org/ (accessed January 17, 2023).
3. 3.↵
   Information on approval of new antibody. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases (accessed January 17, 2023).
4. 4.↵
   Information regarding antibody concentration and formulation composition for newly approved antibody in European Public Assessment Report (EPAR). https://www.ema.europa.eu/en/medicines/human (accessed January 17, 2023).
5. 5.↵
   Information on subcutaneous formulation for Trastuzumab, Herceptin SC. https://www.fda.gov//drugs/drug-approvals-and-databases/fda-approves-new-formulation-herceptin-subcutaneous-use (accessed March 5, 2020).
6. 6.↵
   1. Yang Y.,
   2. Velayudhan A.,
   3. Thornhill N. F.,
   4. Farid S. S.

   Multi-Criteria Manufacturability Indices for Ranking High-Concentration Monoclonal Antibody Formulations. Biotechnol. Bioeng. 2017, 114 (9), 2043–2056.

   OpenUrlCrossRef
7. 7.↵
   1. Drewe E.,
   2. Powell R. J.

   Clinically Useful Monoclonal Antibodies in Treatment. J. Clin. Pathol. 2002, 55 (2), 81–85.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Shieu W.,
   2. Stauch O. B.,
   3. Maa Y.-F.

   Filling of High-Concentration Monoclonal Antibody Formulations into Pre-Filled Syringes: Investigating Formulation-Nozzle Interactions to Minimize Nozzle Clogging. PDA J. Pharm. Sci. Technol. 2015, 69 (3), 417–426.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Sifniotis V.,
   2. Cruz E.,
   3. Eroglu B.,
   4. Kayser V.

   Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation. Antibodies 2019, 8 (2), 36.

   OpenUrlPubMed
10. 10.↵
    1. Shieu W.,
    2. Lamar D.,
    3. Stauch O. B.,
    4. Maa Y.-F.

    Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms That Affect Precision of Low-Volume Fill by Peristaltic Pump. PDA J. Pharm. Sci. Technol. 2016, 70 (2), 143–156.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Wang S. S.,
    2. Yan Y.,
    3. Ho K.

    US FDA Approved Therapeutic Antibodies With High-Concentration Formulation: Summaries and Perspectives. Antibody Ther. 2021, 4 (4), 262–272.

    OpenUrl
12. 12.↵
    1. Collins D. S.,
    2. Sánchez-Félix M.,
    3. Badkar A. V.,
    4. Mrsny R.

    Accelerating the Development of Novel Technologies and Tools for Subcutaneous Delivery of Therapeutics. J. Controlled Release 2020, 321, 475–482. (May

    OpenUrlPubMed
13. 13.↵
    1. Holstein M.,
    2. Hung J.,
    3. Feroz H.,
    4. Ranjan S.,
    5. Du C.,
    6. Ghose S.,
    7. Li Z. J.

    Strategies for High-Concentration Drug Substance Manufacturing to Facilitate Subcutaneous Administration: A Review. Biotechnol. Bioeng. 2020, 117 (11), 3591–3606.

    OpenUrl
14. 14.↵
    1. Jiskoot W.,
    2. Hawe A.,
    3. Menzen T.,
    4. Volkin D. B.,
    5. Crommelin D. J. A.

    Ongoing Challenges to Develop High Concentration Monoclonal Antibody-Based Formulations for Subcutaneous Administration. Quo Vadis? J. Pharm. Sci. 2022, 111 (4), 861–867.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Shukla A. A.,
    2. Wolfe L. S.,
    3. Mostafa S. S.,
    4. Norman C.

    Evolving Trends in mAbs Production Processes. Bioeng. Transl. Med. 2017, 2 (1), 58–69.

    OpenUrlPubMed
16. 16.↵
    1. Hanslip S.,
    2. Desai K. G.,
    3. Palmer M.,
    4. Kemp I.,
    5. Bell S.,
    6. Schofield P.,
    7. Varma P.,
    8. Roche F.,
    9. Colandene J. D.,
    10. Nesta D. P.

    Syringe Filling of a High-Concentration mAb Formulation: Experimental, Theoretical, and Computational Evaluation of Filling Process Parameters That Influence the Propensity for Filling Needle Clogging. J. Pharm. Sci. 2019, 108 (3), 1130–1138.

    OpenUrlPubMed
17. 17.↵
    1. Desai K. G.,
    2. Colandene J. D.,
    3. Gidh A.,
    4. Hanslip S.,
    5. Rastelli M.

    Syringe Filling of High-Concentration mAb Products Using Peristaltic Pump-Based Mechanism: Challenges and Mitigation Strategies. J. Pharm. Sci. 2022, 111 (3), 562–576.

    OpenUrlPubMed
18. 18.↵
    1. Kollár É.,
    2. Balázs B.,
    3. Tari T.,
    4. Siró I.

    Development Challenges of High Concentration Monoclonal Antibody Formulations. Drug Discovery Today: Technol. 2020, 37, 31–40.

    OpenUrl
19. 19.↵
    1. Johnson B.,
    2. Rostovtsev A.

    High Concentration Biologic Formulations: Challenges and Solutions. Drug Discovery Dev. [Online] June 29, 2017, https://www.drugdiscoverytrends.com/high-concentration-biologic-formulations-challenges-and-solutions/ (accessed June 29, 2017).
20. 20.↵
    SIELC, Inc. New Mixed-Mode HILIC - Advances in Retention Control and Selectivity, September 2007 Newsletter. https://www.sielc.com/wp-content/uploads/2015/11/SIELC_September_2007.pdf (accessed December 19, 2019).
21. 21.↵
    1. Bhandare P.,
    2. Madhavan P.,
    3. Rao B. M.,
    4. Rao N. S.

    Determination of Amino Acid without Derivatization by Using HPLC - HILIC Column. J. Chem. Pharm. Res. 2010, 2 (2), 372–380.

    OpenUrl
22. 22.↵
    1. Yadav S.,
    2. Shire S. J.,
    3. Kalonia D. S.

    Viscosity Behavior of High-Concentration Monoclonal Antibody Solutions: Correlation with Interaction Parameter and Electroviscous Effects. J. Pharm. Sci. 2012, 101 (3), 998–1011.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Shire S. J.

    Strategies to Deal with Challenges of Developing High-Concentration Subcutaneous (SC) Formulations for Monoclonal Antibodies (mAbs). In: Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product; Woodhead Publishing: Cambridge, 2015; pp 139–190.
24. 24.↵
    1. Appelblad P.,
    2. Jonsson T.,
    3. Pontén E.,
    4. Jiang W.

    A Practical Guide to HILIC Including ZIC^®-HILIC Applications; MerckSeQuant AB: Darmstadt, Germany, 2009; pp 1–33.
25. 25.↵
    1. Deokar V.,
    2. Sharma A.,
    3. Mody R.,
    4. Volety S. M.

    Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody. J. Pharm. Sci. 2020, 109 (12), 3579–3589.

    OpenUrlPubMed
26. 26.↵
    1. Felsovalyi F.,
    2. Janvier S.,
    3. Jouffray S.,
    4. Soukiassian H.,
    5. Mangiagalli P.

    Silicone-Oil-Based Sub Visible Particles: Their Detection, Interactions, and Regulation in Prefilled Container Closure Systems for Biopharmaceuticals. J. Pharm. Sci. 2012, 101 (12), 4569–4583.

    OpenUrlPubMed
27. 27.↵
    1. Maa Y,
    2. Nguyen P.

    Method of Spray Freeze Drying Proteins for Pharmaceutical Administration. U.S. Patent 6,284,282 B1, September 4, 2001.
28. 28.↵
    1. Sonner C.,
    2. Maa Y.-F.,
    3. Lee G.

    Spray-Freeze-Drying for Protein Powder Preparation: Particle Characterization and a Case Study with Trypsinogen Stability. J Pharm Sci 2002, 91 (10), 2122–2139.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Bluemel O.,
    2. Buecheler J. W.,
    3. Rodrigues M. A.,
    4. Geraldes V.,
    5. Hoelzl G.,
    6. Bechtold-Peters K.,
    7. Friess W.

    Cryoconcentration and 3D Temperature Profiles During Freezing of mAb Solutions in Large-Scale PET Bottles and a Novel Scale-Down Device. Pharm. Res. 2020, 37 (9), 179 Aug 30.

    OpenUrlPubMed
30. 30.↵
    1. Rayfield W. J.,
    2. Kandula S.,
    3. Khan H.,
    4. Tugcu N.

    Impact of Freeze/Thaw Process on Drug Substance Storage of Therapeutics. J. Pharm. Sci. 2017, 106 (8), 1944–1951.

    OpenUrlPubMed
31. 31.↵
    Merck Millipore Filtration Guide for Durapore filter. Durapore® Membrane Filters - Filter Discs and Membranes. merckmillipore.com (accessed January 17, 2023).
32. 32.↵
    1. Siew A.

    Delivering High-Concentration Protein Formulations. Pharm. Technol. 2018, 42 (4), 30–33.

    OpenUrl
33. 33.↵
    1. Prasetyono T. O. H.,
    2. Adhistana P.

    Laboratory Study on Injection Force Measurement on Syringe and Needle Combinations. Malays. J. Med. Sci. 2019, 26 (2), 66–76.

    OpenUrlCrossRef
34. 34.↵
    International Organization for Standardization. ISO 11040-8:2016 Prefilled syringes — Part 8: Requirements and Test Methods for Finished Prefilled Syringes. https://www.iso.org/standard/66036.html (accessed March 1, 2020).
35. 35.↵
    1. Wang W.

    Advanced Protein Formulations. Protein Sci. 2015, 24 (7), 1031–1039.

    OpenUrlPubMed
36. 36.↵
    1. Pabari R. M.,
    2. Ryan B.,
    3. McCarthy C.,
    4. Ramtoola Z.

    Effect of Microencapsulation Shear Stress on the Structural Integrity and Biological Activity of a Model Monoclonal Antibody, Trastuzumab. Pharmaceutics 2011, 3 (3), 510–524.

    OpenUrlCrossRefPubMed
37. 37.
    1. Das N.

    Commercializing High-Concentration mAbs. BioPharm Int. 2016, 29 (11), 47–49.

    OpenUrl
38. 38.
    1. Berteau C.,
    2. Filipe-Santos O.,
    3. Wang T.,
    4. Rojas H.,
    5. Granger C.,
    6. Schwarzenbach F.

    Evaluation of the Impact of Viscosity, Injection Volume, and Injection Flow Rate on Subcutaneous Injection Tolerance. Med. Devices: Evidence Res. 2015, 8, 473–484.

    OpenUrl
39. 39.
    1. Mathaes R.,
    2. Koulov A.,
    3. Joerg S.,
    4. Mahler H-C.

    Subcutaneous Injection Volume of Biopharmaceuticals-Pushing the Boundaries. J. Pharm. Sci. 2016, 105 (8), 2255–2259.

    OpenUrlCrossRefPubMed
40. 40.
    1. Whitaker N.,
    2. Xiong J.,
    3. Pace S. E.,
    4. Kumar V.,
    5. Middaugh C. R.,
    6. Joshi S. B.,
    7. Volkin D. B.

    A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities. J. Pharm. Sci. 2017, 106 (11), 3230–3241.

    OpenUrlCrossRefPubMed
41. 41.
    1. Jezek J.,
    2. Rides M.,
    3. Derham B.,
    4. Moore J.,
    5. Cerasoli E.,
    6. Simler R.,
    7. Perez-Ramirez B.

    Viscosity of Concentrated Therapeutic Protein Compositions. Adv. Drug Delivery Rev. 2011, 63 (13), 1107–1117.

    OpenUrlCrossRefPubMed
42. 42.
    1. Gikanga B.,
    2. Turok R.,
    3. Hui A.,
    4. Bowen M.,
    5. Stauch O. B.,
    6. Maa Y.-F.

    Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 59–73.

    OpenUrlAbstract/FREE Full Text
43. 43.
    1. Burnouf T.,
    2. Sayed M. A.,
    3. Radosevich M.,
    4. El-Ekiaby M.

    Comparative Removal of Solvent and Detergent Viral Inactivating Agents from Human Intravenous Immunoglobulin G Preparations Using SDR Hyper D and C18 Sorbents. Anal. Biochem. 2009, 389 (1), 69–73.

    OpenUrlPubMed